Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study

Roger Cady1,2,3, Richard B. Lipton4, Dawn C. Buse4,5, Mette Krog Josiassen6, Annika Lindsten6 and Anders Ettrup6*

Abstract

Background: The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication effectiveness using the 4-item Migraine Treatment Optimization Questionnaire (mTOQ-4) to measure acute medication optimization over 4 weeks post-infusion.

Methods: RELIEF was a 12-week, phase 3, multicenter, parallel-group, double-blind, placebo-controlled clinical trial conducted in patients aged 18–75 years with a ≥ 1-year history of migraine and 4–15 migraine days per month in the 3 months prior to screening. Patients were randomized 1:1 to a 30-min infusion of eptinezumab 100 mg or placebo within 1–6 h of a qualifying migraine attack. The mTOQ-6 and 6-item Headache Impact Test (HIT-6) were administered at screening visit and week 4. From the mTOQ-6, we calculated the mTOQ-4 using the following items: "2-h pain free," "24-h relief," "able to plan," and "feeling in control" to measure acute medication optimization.

Results: A total of 238 patients received eptinezumab 100 mg and 226 provided week 4 data; 242 received placebo and 232 provided week 4 data. In the eptinezumab arm, the proportion of patients with moderate/maximal optimization increased from 31.4% at baseline to 58.0% (26.6 percentage point increase) at week 4. The corresponding proportions in the placebo group were 40.5% to 50.4% (9.9 percentage point increase). Eptinezumab treatment was associated with numerically larger improvements in HIT-6 at week 4. Relative improvements with eptinezumab vs. placebo from baseline to week 4 in HIT-6 were greater in those with poor treatment optimization at baseline.

Conclusions: In comparison with placebo, treatment with eptinezumab was associated with improvements in acute medication optimization as measured by mTOQ and reductions in headache impact, as measured by HIT-6. These benefits were greater in those with poor acute treatment optimization prior to preventive treatment with eptinezumab.

Trial registration: ClinicalTrials.gov identifier: NCT04152083.

Keywords: Migraine, Eptinezumab, CGRP, mTOQ

Introduction

Migraine is among the world's most disabling disorders, ranking second globally for years of life lived with a disability [1]. The estimated prevalence of migraine is 14%
globally [2]. Despite the high burden of migraine, highlighting the need for effective therapy, migraine remains underdiagnosed and undertreated [3]. Less than half of those with migraine seek medical care and receive a migraine diagnosis [4]. Ideally, preventive treatment should reduce the frequency, severity, and duration of migraine episodes, while slowing disease progression [5]. Acute treatment should safely and rapidly alleviate an episode, within 2 h of treatment [6]. Yet, effective acute treatment of migraine episodes remains a challenge; approximately 34% of patients respond poorly to treatment, which may lead to increased severity in symptoms and disability levels [7]. If the acute medication is not working optimally, it renders the patient at risk for a vicious cycle that can lead to migraine disease progression and medication-overuse headache (MOH) [8]. Furthermore, ineffective acute treatment in patients with episodic migraine is associated with an increased risk of chronic migraine onset, sometimes referred to as migraine chronification [9, 10]. The majority of individuals with migraine use acute therapies, including both over-the-counter and prescription options [9]. Despite advances in preventive treatment, including the development of the calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and gepants, acute medications continue to be needed by most patients to manage breakthrough attacks of migraine [11].

Treatment with eptinezumab, a humanized IgG1 monoclonal antibody that binds the CGRP ligand with high affinity, was associated with statistically significant reductions in mean monthly migraine days over weeks 1–12 in comparison with placebo for both episodic and chronic migraine (PROMISE-1 and PROMISE-2) [12–14]. Another phase 3, multicenter, double-blind trial (RELIEF) in patients eligible for preventive migraine treatment (experiencing migraine 4–15 days/month), found that eptinezumab, administered during a migraine attack, was associated with reduction in headache pain intensity and most bothersome migraine-associated symptoms. Eptinezumab also resulted in less use of rescue medication during the attack as compared with placebo [15]. Additionally, when compared to placebo, eptinezumab-treated patients demonstrated greater improvement in acute treatment response during subsequent migraine attacks as measured by the prespecified 6-item Migraine Treatment Optimization Questionnaire (mTOQ-6) total score [16].

Previous research showed that mTOQ-4, a shortform of mTOQ-6, was a reliable tool for assessing acute medication optimization [9]. This post hoc analysis of the RELIEF study was conducted to investigate the impact of eptinezumab on the optimization of acute medication use, using mTOQ-4, over 4 weeks following administration during a migraine attack in patients eligible for preventive treatment. Secondary analyses included evaluating changes in headache-related impact and acute medication optimization across patients grouped by their baseline acute medication optimization.

**Methods**

**Study design and patients**

Detailed methodology for RELIEF has been published [15]. Briefly, RELIEF was a 4- to 12-week, phase 3, multicenter, parallel-group, double-blind, placebo-controlled clinical trial conducted between November 2019 and July 2020 (NCT04152083) in which patients were randomized to receive eptinezumab 100 mg or placebo. Patients were between the ages of 18–75 years (inclusive) with ≥1-year history of migraine (defined by the International Classification of Headache Disorders, 3rd edition [ICHD-3] criteria [5]), with or without aura, with onset of first migraine before age 50 years, and migraine on 4–15 days per month in the 3 months prior to screening. Patients were required to have typical migraine attacks with a duration of 4–72 h if untreated, with headache pain of moderate to severe intensity and a prespecified most bothersome symptom of nausea, photophobia, or phonophobia. Additionally, patients were required to have a history of either previous or active use of triptans for acute treatment of migraine. Treatment (total volume of 100 mL) was administered intravenously over a period of 30 min on day 0 within 1–6 h of onset of the qualifying migraine attack of moderate to severe intensity.

**Outcome measures**

Patient-reported outcome measures included the mTOQ-6 and 6-item Headache Impact Test (HIT-6). The mTOQ-6 and HIT-6 were captured at baseline and at week 4. The mTOQ-6 data was transformed into the mTOQ-4 for the purposes of these analyses.

The mTOQ-6 is a self-report questionnaire used to assess the optimization of acute treatment in persons with migraine. The 6 mTOQ items are as follows: (1) “Are you able to quickly return to your normal activities (i.e., work, family, leisure, social activities) after taking your migraine medication?” (2) “Can you count on your migraine medication to relieve your pain within 2 h for most attacks?” (3) Does one dose of your migraine medication usually relieve your headache and keep it away for at least 24 h?” (4) “Is your migraine medication well tolerated?” (5) “Are you comfortable enough with your migraine medication to be able to plan your daily activities?” (6) “After taking your migraine medication, do you feel in control of your migraines enough so that you feel there will be no disruption to your daily activities?” [17]. Each of the 6 items is scored as never (1), rarely (2), less
than half the time (3), and half the time or more (4). The mTOQ-6 total score is calculated by summing individual question scores (score range of 6–24), with higher scores indicating better acute treatment optimization [17].

In addition to the mTOQ-6 scores, the developers provide a simplified scoring for the mTOQ-4 by selecting the items that best assessed treatment efficacy: “2-h pain free,” “24-h relief,” “able to plan,” and “feeling in control” [9]. Items evaluating “tolerability” and “quick return to function” were excluded because they were either unrelated or redundant [9]. For analysis purposes, the item scores were classified (combining rarely and less than half the time) and new scores were assigned as never (0), rarely (0), less than half the time (1), and at least half the time (2), and then summed for total score. Patients were then grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). A simplified grouping combined very poor with poor (0–5) and moderate with maximal (6–8).

The HIT-6 is a self-reported assessment of the impact on the ability to function normally in daily life when a headache occurs [18]. Each of the 6 items is scored as never (6), rarely (8), sometimes (10), very often (11), and always (13). The HIT-6 total score is calculated by summing individual items (score range of 36–78 points), with the total score representing headache-related life impact: severe impact = ≥ 60, substantial impact = 56–59, some impact = 50–55, and little to no impact = ≤ 49.

**Statistical analysis**
For the mTOQ-6 and HIT-6, total scores were summarized by treatment group at baseline and week 4 (or early termination) and change from baseline to the week 4 visit was calculated. If response was missing for ≥ 1 item of the HIT-6 or mTOQ-6, the respective total score was treated as missing; no missing data were imputed. As a post hoc analysis, all results are summarized descriptively.

**Results**
Baseline demographics and characteristics have been reported and showed similarity between eptinezumab and placebo groups [15]. A total of 238 and 242 patients were randomized to receive eptinezumab 100 mg or placebo, respectively; week 4 data were available for the present analysis for 226 patients treated with eptinezumab and 232 receiving placebo.

At baseline, the greatest proportion of patients in both groups had poor acute treatment optimization, with less
than 14% having maximal optimization (Fig. 1). The distribution at post-treatment week 4 shows a greater shift toward maximal acute treatment optimization, with an increase over baseline of 22.2 percentage points for the eptinezumab treatment group compared with 13.8 percentage points for the placebo group (Fig. 1). Acute treatment optimization distributions were simplified into “poorly optimized” (“very poor” and “poor” categories) and “optimized” (“moderate” and “maximal” categories). The percentage of patients who were “optimized” increased by 26.6 percentage points with eptinezumab compared with 9.9 percentage points with placebo (Fig. 2). Of the 155 eptinezumab-treated patients who were very poorly or poorly optimized at baseline, 73 (47.1%) were moderately or maximally optimized at week 4, respectively; in comparison, of the 138 patients receiving placebo, 35 (25.4%) were moderately or maximally optimized.

Mean mTOQ-6 total scores at baseline and week 4 by baseline acute treatment optimization subgroups are summarized in Table 1. Across subgroups, eptinezumab treatment resulted in numerically larger improvements than placebo in mTOQ-6 total score at week 4, with a trend of larger improvements in subgroups with worse optimization at baseline (Fig. 3). Mean change from baseline to week 4 in mTOQ-6 total score in eptinezumab-treated patients very poorly optimized at baseline was 4.9 versus 2.4 in patients receiving placebo (Fig. 3).

Mean HIT-6 total scores at baseline were 66.6–69.6, 65.0–66.0, 63.2–64.7, and 62.5–63.5 points in the very poor, poor, moderate, and maximal optimization subgroups, respectively (Table 2). Similar to the mTOQ-6, eptinezumab treatment was associated with numerically larger improvements than placebo in HIT-6 total score at week 4 (Fig. 4). Patients with very poor baseline optimization reported the greatest amount of change (−11.2 with eptinezumab vs. −2.2 with placebo from baseline to week 4) (Fig. 4).

Discussion
Primary results from the RELIEF study showed that eptinezumab, when administered within 1–6 h of a migraine attack, provided shorter time to headache pain freedom and absence of most bothersome symptom after the start of infusion compared with placebo [15]. In this post hoc analysis, the effects of eptinezumab compared with placebo on acute treatment optimization and headache-related impact were explored in patients grouped by...
their level of acute medication optimization at baseline. These analyses from the RELIEF study show that eptinezumab, after demonstrating effects on the active migraine attack, resulted in numerically larger improvements in the proportion of patients with optimized acute medication at week 4 and was associated with numerically larger improvements in mTOQ-6 total score and HIT-6 total score at week 4 when compared with placebo. Given its half-life of 27 days [19], eptinezumab may have a unique role in effectively treating an active migraine attack and remaining active to work synergistically with traditional acute treatments to optimize treatment of future breakthrough migraine attacks.

The mTOQ-6 was transformed into the mTOQ-4 in alignment with the developers’ modification, which has demonstrated usefulness as a tool in determining acute medication optimization and thus is useful in determining how preventive treatment may impact the effectiveness of acute medication [9]. Results from this post hoc analysis showed that, numerically, more patients treated with eptinezumab shifted from having poorly optimized to optimized acute treatment. In addition, the trend of larger improvements in mTOQ-6 total score in patients with poorer optimization at baseline suggests that eptinezumab may work synergistically with acute medications to better control acute breakthrough attacks of migraine.

Likewise, better response to acute intervention may work synergistically with preventive treatment to prevent migraine chronification.

Changes from baseline in HIT-6 total score did not show a clear trend of increasing improvement with poorer baseline optimization; however, eptinezumab treatment was associated with numerically larger improvements than placebo in HIT-6 total score at week 4, similar to the mTOQ-6 [16]. The most pronounced effects were noted in very poorly optimized patients, which may include patients who are potentially stuck in the vicious cycle of medication overuse and MOH. These data highlight the potential benefit of eptinezumab in optimizing acute medication use during breakthrough attacks and suggest that eptinezumab may reduce the overall impact and severity of migraine, potentially lowering the risk of migraine chronification.

There is currently a lack of studies that demonstrate a causative link between effective preventive migraine treatment and improved acute medication optimization. Previous research has indicated that acute medication is less effective in patients with higher frequency of monthly headache days, more severe migraine attacks, and MOH, with current use of preventive migraine treatment associated with increased effectiveness [20]. The recent introduction of CGRP-targeting therapy in clinical

| Optimization subgroup | Time point | Eptinezumab 100 mg | Mean (SD) [n] | Placebo | Mean (SD) [n] |
|-----------------------|------------|--------------------|---------------|---------|---------------|
| Very poor             | Baseline   | 11.2 (2.4) [25]    | 11.6 (2.2) [25] |         |               |
|                       | Week 4     | 16.2 (5.3) [25]    | 13.9 (5.5) [24] |         |               |
|                       | Change from baseline | 4.9 (4.9) [25] | 2.4 (5.1) [24] |         |               |
| Poor                  | Baseline   | 17.0 (2.6) [138]   | 16.8 (2.7) [117] |         |               |
|                       | Week 4     | 19.6 (4.1) [130]   | 18.4 (3.3) [114] |         |               |
|                       | Change from baseline | 2.5 (4.2) [130] | 1.5 (3.0) [114] |         |               |
| Moderate              | Baseline   | 21.5 (1.2) [46]    | 21.9 (1.0) [65] |         |               |
|                       | Week 4     | 22.1 (2.1) [44]    | 22.2 (2.0) [63] |         |               |
|                       | Change from baseline | 0.6 (2.0) [44] | 0.3 (1.8) [63] |         |               |
| Maximal               | Baseline   | 23.8 (0.5) [28]    | 23.8 (0.5) [35] |         |               |
|                       | Week 4     | 23.1 (1.8) [26]    | 23.2 (2.0) [30] |         |               |
|                       | Change from baseline | -0.7 (1.9) [26] | -0.7 (2.0) [30] |         |               |
| Simplified subgroups  |            |                    |               |         |               |
| Poorly optimized      | Baseline   | 16.1 (3.3) [163]   | 15.9 (3.3) [142] |         |               |
|                       | Week 4     | 19.0 (4.5) [155]   | 17.6 (4.1) [138] |         |               |
|                       | Change from baseline | 2.9 (4.4) [155] | 1.7 (3.5) [138] |         |               |
| Optimized             | Baseline   | 22.4 (1.5) [75]    | 22.6 (1.2) [100] |         |               |
|                       | Week 4     | 22.5 (2.0) [71]    | 22.6 (2.0) [93]  |         |               |
|                       | Change from baseline | 0.1 (2.1) [71] | 0.0 (1.9) [93]  |         |               |

Patients were grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). Simplified subgroups consist of patients with mTOQ-4 total scores in very poor (0) and poor (1–5) categories together, along with patients with total scores in the moderate (6–7) and maximal (8) categories grouped together. Epti, eptinezumab (100 mg); mTOQ-4/mTOQ-6, 4-item/6-item Migraine Treatment Optimization Questionnaire.
Fig. 3 Change from baseline to week 4 in mTOQ-6 total score by baseline acute treatment optimization subgroup. Patients were grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). The mTOQ-6 total score ranges from 6 to 24, with higher scores indicating better acute medication optimization. Epti, eptinezumab (100 mg); mTOQ-4/mTOQ-6, 4-item/6-item Migraine Treatment Optimization Questionnaire.

Table 2 HIT-6 total score at baseline and week 4 by baseline acute treatment optimization subgroup

| Optimization subgroup | Time point    | Eptinezumab 100 mg | Placebo |
|-----------------------|--------------|-------------------|---------|
|                       | Mean (SD) [n] | Mean (SD) [n]     |         |
|                       | Baseline     | 69.6 (4.6) [25]   | 66.6 (4.6) [25] |
|                       | Week 4       | 58.4 (11.8) [25]  | 64.5 (7.5) [24]  |
| Very poor             | Change from baseline | -11.2 (12.2) [25] | -2.2 (6.9) [24] |
| Poor                  | Baseline     | 65.0 (4.6) [138]  | 66.0 (4.6) [117] |
|                       | Week 4       | 57.1 (9.5) [130]  | 62.0 (7.8) [114] |
|                       | Change from baseline | -7.7 (10.3) [130] | -4.0 (7.2) [114] |
| Moderate              | Baseline     | 64.7 (4.6) [46]   | 63.7 (5.2) [63]  |
|                       | Week 4       | 57.3 (8.9) [44]   | 59.4 (7.6) [63]  |
|                       | Change from baseline | -7.1 (9.0) [44]  | -3.8 (8.5) [63] |
| Maximal               | Baseline     | 63.5 (5.2) [29]   | 62.5 (4.8) [35]  |
|                       | Week 4       | 54.7 (10.1) [27]  | 58.7 (7.8) [31]  |
|                       | Change from baseline | -8.6 (11.0) [27] | -3.6 (8.4) [31] |
| Simplified subgroups  | Poorly optimized | Baseline | 65.7 (4.9) [163] | 66.1 (4.6) [142] |
|                       | Week 4       | 57.3 (9.9) [155]  | 62.4 (7.7) [136] |
|                       | Change from baseline | -8.3 (10.7) [155] | -3.7 (7.2) [136] |
| Optimized             | Baseline     | 64.3 (4.6) [75]   | 62.9 (5.0) [100] |
|                       | Week 4       | 56.4 (9.4) [71]   | 59.2 (7.6) [94]  |
|                       | Change from baseline | -7.7 (9.7) [71]  | -3.7 (8.5) [94] |

Patients were grouped by baseline mTOQ-4 total scores into the following optimization categories: very poor (0), poor (1–5), moderate (6–7), and maximal (8). The HIT-6 total score ranges from 36 to 78, with higher scores indicating more severe headache-related impact. Simplified subgroups consist of patients with mTOQ-4 total scores in very poor (0) and poor (1–5) categories together, along with patients with total scores in the moderate (6–7) and maximal (8) categories grouped together. Epti, eptinezumab (100 mg); HIT-6, 6-item Headache Impact Test; mTOQ-4, 4-item Migraine Treatment Optimization Questionnaire.
practice presents the opportunity to find appropriate conditioning, and potentially combination therapy, of different drug classes (antidepressants, triptans, gepants, onabotulinumtoxinA) [21]. Though a causal effect cannot be determined in the current post hoc analysis, the results suggest that eptinezumab—which has been shown to reduce migraine and headache frequency and severity and days of acute headache medication use in patients with episodic migraine [13, 22], chronic migraine [23–25], and chronic migraine with MOH [26, 27],—may prevent chronification, which could aid in decoupling the cycle of chronic migraine and MOH [8], and that eptinezumab may have an enduring effect on acute treatment optimization.

Limitations
These analyses are primarily limited by their post hoc nature, where only summary statistics were reported, and by smaller sample sizes of some subgroups. To date, there are no other reports that have studied mTOQ-4 scores in patients before and after initiation of preventive migraine treatment. However, the design of RELIEF limits the ability to connect the preventive migraine efficacy of eptinezumab to the changes observed on patient-reported outcomes, though it has been shown that the preventive effect of eptinezumab can be observed as early as the day after infusion [28]. These analyses did not exclude patients who did not experience a new migraine during the 4-week treatment period, which occurred more frequently in the eptinezumab group than in the placebo group [16]. The effects of not experiencing another migraine attack in the study may over- or underestimate patient-reported evaluation of acute treatment optimization. In addition, the impact of specific items of the mTOQ-4 and HIT-6 were not explored; thus, it is unknown which factors of migraine impact were most affected by reduced acute treatment optimization. Lastly, the use of mTOQ-4 as the primary measure is somewhat limited in those patients who were optimized at baseline due to difficulty in assessing change from baseline in mTOQ-4 score.

Conclusions
In this post hoc analysis, eptinezumab use was associated with greater improvements in response to acute treatment use after administration of eptinezumab during a migraine attack. Regardless of baseline treatment optimization, headache-related life impact also
improved compared to placebo, suggesting that epitnezumab may work synergistically with acute medications and other treatments. These data highlight the potential benefit of epitnezumab in optimizing acute treatment use during breakthrough attacks and suggest that epitnezumab may reduce the overall impact and severity of migraine and potentially lower the risk of migraine chronification. Furthermore, the more pronounced results in poorly optimized patients indicate that those experiencing suboptimal acute medication effectiveness benefit the most from preventive treatment with epitnezumab.

Abbreviations
CGRP: Calcitonin gene-related peptide; HIT-6: 6-Item Headache Impact Test; ICHD-3: International Classification of Headache Disorders, 3rd edition; MOH: Medication-overuse headache; mTOQ-4, 4-item Migraine Treatment Optimization Questionnaire; mTOQ-6: 6-Item Migraine Treatment Optimization Questionnaire.

Acknowledgements
This study was sponsored by H. Lundbeck A/S (Copenhagen, Denmark). The authors thank Roshni Thakkar, PhD, and Nicole Coolbaugh, CMPP, of The Medicine Group, LLC (New Hope, PA, United States) for providing medical writing support, which was funded by H. Lundbeck A/S (Copenhagen, Denmark) and in accordance with Good Publication Practice guidelines.

Authors’ contributions
Conception and design of the work: RC, RBL, AE. Analysis and interpretation: RC, RBL, DCB, MKJ, AL, AE. Drafting of the work: RC, RBL, DCB, MKJ, AL, AE. Revising it critically for important intellectual content: RC, RBL, DCB, MKJ, AL, AE. The author(s) read and approved the final manuscript.

Funding
Sponsored and funded by H. Lundbeck A/S. The sponsor participated in the design and conduct of the study; data collection, management, analysis, and interpretation; and preparation, review, and approval of the manuscript. All authors and H. Lundbeck A/S prepared, reviewed, and approved the manuscript. Editorial support for the development of this manuscript was funded by H. Lundbeck A/S.

Availability of data and materials
In accordance with EFPIA and PhRMA’s “Principles for Responsible Clinical Trial Data Sharing” guidelines, Lundbeck is committed to responsible sharing of clinical trial data in a manner that is consistent with safeguarding the privacy of patients, respecting the integrity of national regulatory systems, and protecting the intellectual property of the sponsor. The protection of intellectual property ensures continued research and innovation in the pharmaceutical industry. Deidentified data are available to those whose request has been reviewed and approved through an application submitted to https://www.lundbeck.com/global/our-science/clinical-data-sharing.

Competing interests
Dr. Cady was an employee of Lundbeck at the time of the study.

Dr. Lipton has been a consultant, advisory board member, and/or has received honoraria from Lundbeck Seattle BioPharmaceuticals, Allergan/AbbVie, American Academy of Neurology, American Headache Society, Amgen, Biohaven Pharmaceuticals, electroCore Medical, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Perkin, Pfizer, Teva Pharmaceuticals, and Vedanta. He holds stock or stock options in Biohaven Pharmaceuticals and Manistee.

Dr. Buse is a part-time employee of Vector Psychometric Group, a company that has received funding from H. Lundbeck A/S for separate research, has received grant support from the US Food and Drug Administration and the National Headache Foundation, has received grant support and honoraria from Allergan, Amgen, Biohaven, Eli Lilly, Novartis, and Teva, and serves on the editorial board of Current Pain and Headache Reports.

Dr. Jossissen, Ms. Lindsten, and Dr. Etrup are employees of Lundbeck.

Author details
1RK Consults, Ozark, MO, United States. 2Missouri State University, Springfield, MO, United States. 3Lundbeck LLC, Deerfield, IL, United States. 4Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States. 5Vector Psychometric Group, LLC, Chapel Hill, NC, United States. 6H. Lundbeck A/S, Copenhagen, Denmark.

Received: 21 June 2022 Accepted: 18 July 2022 Published online: 28 July 2022

References
1.  GBD (2016) Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954–976. https://doi.org/10.1016/s1474-4422(18)30322-3
2.  Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23:34. https://doi.org/10.1186/s10194-022-01402-2
3.  Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
4.  Buse DC, Armand CE, Charleston L et al (2021) Barriers to care in episodic and chronically active migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. Headache 61(4):628–641. https://doi.org/10.1111/ head.14103
5.  Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–221. https://doi.org/10.1177/0331024717738202
6.  Ruzzo PB (2012) Acute and Preventive Treatment of Migraine. Continuum Lifelong Learning Neurology 18:764–782
7.  Lombard L, Ye W, Nichols R et al (2020) A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Improvement in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment. Headache 60:1325–1339. https://doi.org/10.1111/head.13835
8.  Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The Evolution of Medication Overuse Headache: History, Pathophysiology, and Clinical Update. CNS Drugs 35:545–565. https://doi.org/10.1007/s40263-021-00818-9
9.  Lipton RB, Fanning KM, Serrano D et al (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688–695. https://doi.org/10.1212/WNL.0000000000002156
10.  Smitherman TA, rains JC, Penzien DB (2009) Psychiatric comorbidity and migraine chronification. Curr Pain Headache Rep 13:326–331. https://doi.org/10.1007/s11916-009-0052-7
11.  Vandervorst F, van Deun L, van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22:128. https://doi.org/10.1186/s10194-021-01335-2
12.  Garcia-Martinez LF, Raport Cjd, Ojala EW et al (2020) Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide.

Declarations
Ethics approval and consent to participate
Approval for each study was provided by the independent ethics committee or institutional review board of the study site. The study was conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Patients provided written informed consent prior to initiation of any study procedures.

Consent for publication
Not applicable.
J Pharmacol Exp Ther 374:93–103. https://doi.org/10.1124/jpet.119.264671

13. Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241–254. https://doi.org/10.1177/033310242095132

14. Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology 94:e1365–e1377. https://doi.org/10.1212/01.WNL.0000000000009169

15. Winner PK, McAllister P, Chakhava G et al (2021) Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated during a Migraine Attack: A Randomized Clinical Trial. JAMA 325:2348–2356. https://doi.org/10.1001/jama.2021.7665

16. McAllister P, Winner PK, Alani J et al (2022) Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. J Headache Pain 23:22. https://doi.org/10.1186/s10194-021-01376-7

17. Lipton RB, Kolodner K, Bigal ME et al (2009) Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 29:751–759. https://doi.org/10.1111/j.1468-2982.2008.01786.x

18. Kosinski M, Bayliss MS, Bjorner JB et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974. https://doi.org/10.1023/A:1026193311913

19. Baker B, Schaeffer B, Beliveau M et al (2020) Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect 8:e00567. https://doi.org/10.1002/prp2.567

20. Lipton RB, Munjal S, Buse DC et al (2016) Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 56:1635–1648. https://doi.org/10.1111/head.12941

21. Benemeri S, Bentivegna E, Martelletti P (2022) Positioning the new drugs for migraine: Expert Opin Drug Metab Toxicol 18:1–3. https://doi.org/10.1080/17425255.2022.2049236

22. Smith TR, Janelidze M, Chakhava G et al (2020) Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther 42:2254-2265.e3. https://doi.org/10.1016/j.clinthera.2020.11.007

23. Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology 94:e1365–e1377. https://doi.org/10.1212/01.WNL.0000000000009169

24. Silberstein S, Diamond M, Hindiyeh NA et al (2020) Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study. J Headache Pain 21:1–12. https://doi.org/10.1186/s10194-020-01186-3

25. McAllister P, Kudrow D, Cady R, et al (2022) Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia. 3331024221089567.https://doi.org/10.1177/03331024221089567

26. Diener H-C, Marmura MJ, Tepper SJ et al (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 61:125–136. https://doi.org/10.1111/head.14036

27. Marmura MJ, Diener HC, Cowan RP et al (2021) Preventive migraine treatment with eptinezumab reduced acute medication headache and medication frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache 61:1421–1431. https://doi.org/10.1111/head.14206

28. Dodick DW, Gottschalk C, Cady R et al (2020) Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on Day 1 after dosing. Headache 60:2220–2231. https://doi.org/10.1111/head.14007

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.